Esperion Therapeutics ESPR Royalty sale liability
Royalty sale liability at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept espr:RoyaltySaleLiabilityCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's royalty sale liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's royalty sale liability?
- Esperion Therapeutics (ESPR) reported royalty sale liability of $80.75M in Q1 2026.
- How has Esperion Therapeutics's royalty sale liability changed year-over-year?
- Esperion Therapeutics's royalty sale liability increased by 41.1% year-over-year, from $57.24M to $80.75M.
- What does royalty sale liability mean?
- This represents the portion of future royalty revenue streams that has been monetized upfront and is due to be recognized or repaid within one year. It reflects the company's past financing decisions to trade future cash flows for immediate capital. Investors use this to understand the impact of royalty monetization on short-term cash flow and future revenue recognition.